Methods for treating cancer and non-neoplastic conditions

Abstract

Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections, involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.

1 .- 30 . (canceled) 
     
     
         31 . A method of treating a viral infection or of inhibiting or reducing the viral replication or the production of viral RNA or DNA or viral protein in a subject infected with an RNA virus or a DNA virus, comprising administering to the subject an effective amount of a compound of Formula (IV): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein,
 X is halogen; 
 R a  is H, C 1  to C 8  alkyl optionally substituted with one or more substituents independently selected from hydroxyl and halogen; and 
 R d  is phenyl substituted on a para position with a halogen substituent. 
 
       
     
     
         32 . The method of  claim 31 , wherein the compound of Formula (IV) is a compound having the structure: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         33 . The method of  claim 31 , wherein the compound of Formula (IV) is a compound having the structure: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         34 . A method for inhibiting or reducing viral replication or the production of viral RNA or DNA or viral protein, comprising contacting a cell or a cell line infected with an RNA virus or DNA virus with a compound of Formula (IV): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein
 X is halogen; 
 R a  is H, C 1  to C 8  alkyl optionally substituted with one or more substituents independently selected from hydroxyl and halogen; and 
 R d  is phenyl substituted on a para position with a halogen substituent. 
 
       
     
     
         35 . The method of  claim 34 , wherein the compound of Formula (IV) is a compound having the structure: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         36 . The method of  claim 34 , wherein the compound of Formula (IV) is a compound having the structure: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         37 . The method of  claim 31 , wherein the virus is selected from the group consisting of: Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Paramyxoviridae, Picornaviridae, Orthomyxoviridae, Rhabdoviridae, Hepadnaviridae, Reoviridae, Retro viridae, Adenoviridae, Herpesviridae, Papillomaviridae, and Papovaviridae. 
     
     
         38 . The method of  claim 31 , wherein the virus is an RNA virus. 
     
     
         39 . The method of  claim 38 , wherein the RNA virus is selected from the group consisting of: Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Paramyxoviridae, Picornaviridae, Orthomyxoviridae, and Rhabdoviridae. 
     
     
         40 . The method of  claim 38 , wherein the RNA virus belongs to the family Coronaviridae. 
     
     
         41 . The method of  claim 40 , wherein the RNA virus belonging to the family Coronaviridae is a severe acute respiratory syndrome coronavirus (SARS-CoV). 
     
     
         42 . The method of  claim 34 , wherein the virus is selected from the group consisting of: Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Paramyxoviridae, Picornaviridae, Orthomyxoviridae, Rhabdoviridae, Hepadnaviridae, Reoviridae, Retro viridae, Adenoviridae, Herpesviridae, Papillomaviridae, and Papovaviridae. 
     
     
         43 . The method of  claim 43 , wherein the virus is an RNA virus. 
     
     
         44 . The method of  claim 43 , wherein the RNA virus is selected from the group consisting of: Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Paramyxoviridae, Picornaviridae, Orthomyxoviridae, and Rhabdoviridae. 
     
     
         45 . The method of claim  24 , wherein the RNA virus belongs to the family Coronaviridae. 
     
     
         46 . The method of claim  26 , wherein the RNA virus belonging to the family Coronaviridae is a severe acute respiratory syndrome coronavirus (SARS-CoV).